Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.

BACKGROUND Treatment with recombinant human erythropoietin (rHuEPO) has been a major advance for the management of anemia in patients on hemodialysis. Therapy, however, is often observed to be associated with recurrent cyclic fluctuations in hemoglobin levels. The purpose of this analysis was to describe the phenomenology of hemoglobin cycling during rHuEPO treatment. METHODS Data were analyzed for 281 hemodialysis patients treated at Winthrop-University Hospital Dialysis Centers between 1998 and 2003. Eligible patients' first full 1-year period with less than 10 hospital days was studied. Hemoglobin cycling (cycles with amplitude >1.5 g/dL and duration >8 weeks) and excursions (half of one full cycle) were analyzed. RESULTS Greater than 90% of patients experienced hemoglobin cycling. The mean number of hemoglobin excursions was 3.1 +/- 1.1 per patient/year. The mean amplitude per hemoglobin excursion was 2.51 +/- 0.89 g/dL. The mean duration of hemoglobin excursions was 10.3 +/- 5.1 weeks. Factors associated with initiation of up excursions included increases in rHuEPO dose (84%), intravenous iron treatment initiation or increase in dose (27%), posthospital discharge (36%), factors associated with down excursions included rHuEPO dose hold (15%) or dose reduction (62%), infection (6%), discontinuation of intravenous iron therapy (5%), and hospitalization (14%). Patients with frequent hemoglobin cycling (>two full cycles per year) were characterized as being more responsive to rHuEPO [index of EPO responsiveness (ERI) 1036 +/- 659 compared to 1992 +/- 701 for other patients] (P = 0.02). CONCLUSION Hemoglobin cycling is a common occurrence in rHuEPO-treated hemodialysis patients. It is most closely associated with frequent rHuEPO dose changes, hospitalization, and iron treatment practices.

[1]  K. Koch,et al.  Anemia of the regular hemodialysis patient and its treatment. , 1974, Nephron.

[2]  J. Sadoshima,et al.  Signal transduction pathways of angiotensin II--induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. , 1993, Circulation research.

[3]  J. Adamson.  Erythropoietin: its role in the regulation of erythropoiesis and as a therapeutic in humans. , 1991, Biotechnology.

[4]  M. Allon,et al.  Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  J. Fandrey.  Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  S. Fishbane,et al.  Beneficial effects of iron therapy in renal failure patients on hemodialysis. , 1999, Kidney international. Supplement.

[7]  S. Fishbane,et al.  Hemoglobin variability in epoetin-treated hemodialysis patients. , 2003, Kidney international.

[8]  R. Longnecker,et al.  Blood loss during maintenance hemodialysis. , 1974, Transactions - American Society for Artificial Internal Organs.

[9]  J. Lazarus,et al.  Effect of variability in anemia management on hemoglobin outcomes in ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  R. Foley,et al.  Effects of anaemia on cardiovascular status. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  A. Heidland,et al.  Treatment of the Anemia of Hemodialysis Patients with Recombinant Human Erythropoietin , 1988, The International journal of artificial organs.

[12]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[13]  M. Tonelli,et al.  Predictors of Erythropoietin Responsiveness in Chronic Hemodialysis Patients , 2001, ASAIO journal.

[14]  G. Kaysen,et al.  Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  J. Adamson,et al.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. , 1987, The New England journal of medicine.

[16]  A. Collins,et al.  Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. , 2004, Kidney international.

[17]  S. Fishbane,et al.  The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. , 1995, Clinical nephrology.

[18]  M. Gassmann,et al.  Erythropoietin Protects from Axotomy-induced Degeneration of Retinal Ganglion Cells by Activating Erk-1/-2 Retrograde Labeling of Rgcs Inhibition of Erk-1/2 and Phosphatidyl Inositol-3′ Kinase (pi3k)/akt Pathways Immunohistochemical Detection of Epo Receptor Erk-1/-2 and Akt Signaling Are Increased, , 2022 .

[19]  J. Adamson,et al.  Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. , 1989, Annals of internal medicine.

[20]  P. Ghezzi,et al.  Effects of epoetin alfa on the central nervous system. , 2001, Seminars in oncology.

[21]  A. Collins,et al.  Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. , 2001, Journal of the American Society of Nephrology : JASN.

[22]  M. Bogoyevitch.  An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. , 2004, Cardiovascular research.

[23]  F. Farrell,et al.  The erythropoietin receptor and its expression in tumor cells and other tissues. , 2004, The oncologist.

[24]  C. Westenfelder.  Unexpected Renal Actions of Erythropoietin , 2002, Nephron Experimental Nephrology.

[25]  J. Adamson,et al.  IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  K. Gunawardena,et al.  Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly , 2001, European Journal of Clinical Pharmacology.

[27]  A. Collins,et al.  Impact of hematocrit on morbidity and mortality. , 2000, Seminars in nephrology.

[28]  B. Molitoris,et al.  Erythropoietin Requirements Increase following Hospitalization in End-Stage Renal Disease Patients , 2001, American Journal of Nephrology.